UCSF BTC Clinical Trials

A Study of Ramucirumab (LY3009806) in Children With Refractory Solid Tumors

Summary

The purpose of this Phase I clinical trial is to evaluate the safety and efficacy of the drug ramucirumab, in treating children with recurrent or refractory solid tumors (including central nervous system tumors).

Ramucirumab is an antibody that specifically binds to and inhibits VEGFR2, a protein involved in promoting blood vessel growth (or angiogenesis) in tumors. By blocking the activity of VEGFR2, ramucirumab may help inhibit tumor angiogenesis and decrease the nutrient supply to the tumor.

In this phase I study, all eligible participants will receive the following treatment:

  • Experimental: Ramucirumab

 

Inclusion Criteria
  1. Part A: participants with recurrent or refractory non-CNS solid tumors
  2. Part B: participants with recurrent or refractory CNS tumors
  3. Measurable or evaluable disease
  4. No other therapeutic options
  5. Performance Status: Karnofsky ≥50% for participants >16 years and Lansky ≥50 for participants ≤16 years

For the most up-to-date list of criteria, please visit clinicaltrials.gov.

Exclusion Criteria
  1. Active or recent history of serious bleeding events
  2. Active or recent history of gastrointestinal perforations, ulcers, fistulas or abscesses
  3. Active or recent history of hypertensive crisis or hypertensive encephalopathy
  4. Active non-healing wound or bone fracture
  5. History of solid organ transplant

For the most up-to-date list of criteria, please visit clinicaltrials.gov.

Stay Informed